We read with great interest the article entitled "Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma (laBCC) with the hedgehog inhibitor vismodegib: a single center experience" recently published in your journal and we want to report also our experience regarding the effect of dose reduction of hedgehog inhibitor vismodegib treatment as a new therapeutic option in order to reduce the high frequency of adverse events and increase patients compliance. This article is protected by copyright. All rights reserved.

Reply to Woltsche N. et al. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single center experience

Scalvenzi, M;Costa, C;Cappello, M;Villani, A
2019

Abstract

We read with great interest the article entitled "Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma (laBCC) with the hedgehog inhibitor vismodegib: a single center experience" recently published in your journal and we want to report also our experience regarding the effect of dose reduction of hedgehog inhibitor vismodegib treatment as a new therapeutic option in order to reduce the high frequency of adverse events and increase patients compliance. This article is protected by copyright. All rights reserved.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11588/747533
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 17
social impact